Zenas BioPharma, Inc. (ZBIO)

NASDAQ: ZBIO · Real-Time Price · USD

25.87

+1.20 (4.86%)

At close: Jun 26, 2026, 4:00 PM EDT

26.99

+1.12 (4.33%)

After-hours: Jun 26, 2026, 7:58 PM EDT

Zenas BioPharma Employees

Zenas BioPharma had 167 employees as of December 31, 2025. The number of employees increased by 37 or 28.46% compared to the previous year.

Employees

167

Change (1Y)

37

Growth (1Y)

28.46%

Revenue / Employee

n/a

Profits / Employee

-$2,545,814

Market Cap

1.63B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2025	167	37	28.46%
Dec 31, 2024	130	-	-

Related Stocks

Company Name	Employees
Ascentage Pharma Group International	767
Immunocore Holdings	524
Ardelyx	489
Maravai LifeSciences Holdings	416
Maze Therapeutics	141
Absci	140
MapLight Therapeutics	133
Septerna	130

Employee Rankings

ZBIO News

10 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
13 days ago - Zenas BioPharma Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
16 days ago - Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - GlobeNewsWire
25 days ago - Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine - GlobeNewsWire
26 days ago - Zenas BioPharma Slides: Corporate presentation - Filings
4 weeks ago - Zenas BioPharma submits BLA to FDA for obexelimab - TheFly
4 weeks ago - Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD - GlobeNewsWire
5 weeks ago - Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress - GlobeNewsWire